Cullinan Therapeutics, Inc. (CGEM): Total Assets
$448.37M
As of 2025-12-31
$363.79M
As of 2026-06-30
-7.2%
3-year compound annual growth
+15.9%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $448.37M | -27.9% | 2026-03-10, Balance as of period end |
| 2024-12-31 | $621.82M | +28.4% | 2026-03-10, Balance as of period end |
| 2023-12-31 | $484.18M | -13.7% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $561.12M | +28.3% | 2024-03-14, Balance as of period end |
| 2021-12-31 | $437.19M | +103.6% | 2023-03-09, Balance as of period end |
| 2020-12-31 | $214.71M | n/a | 2022-03-17, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | 2025-12-31 | $448.37M | -27.9% |
| Monte Rosa Therapeutics, Inc. (GLUE) | 2025-12-31 | $448.66M | +2.3% |
| REGENXBIO Inc. (RGNX) | 2025-12-31 | $453.03M | -2.8% |
| Vor Biopharma Inc. (VOR) | 2025-12-31 | $464.13M | +224.8% |
| Sana Biotechnology, Inc. (SANA) | 2025-12-31 | $416.89M | -16.8% |
| Allogene Therapeutics, Inc. (ALLO) | 2025-12-31 | $415.90M | -24.2% |
| Vericel Corp (VCEL) | 2025-12-31 | $487.97M | +12.8% |
| Scholar Rock Holding Corp (SRRK) | 2025-12-31 | $404.27M | -14.9% |
| ImmunityBio, Inc. (IBRX) | 2025-12-31 | $501.90M | +31.1% |
Compare CGEM, GLUE, RGNX, VOR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗